Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some. However, these innovative new treatments must come with equally innovative programs to optimize access in a global healthcare market that is still grappling with how to fairly assess their value and absorb their higher upfront costs. Nonetheless, the pipeline for gene therapies is burgeoning, as large pharmaceutical companies (e.g., Novartis, Johnson & Johnson) take an increasing stake in this arena. Here, we explore the clinical and commercial potential of gene therapies in key therapeutic areas (i.e., neurology, ophthalmology, and hematology).
- What are the sizes of the eligible populations for gene therapies in key indications across the G7?
- What are the key advantages and disadvantages of marketed gene therapies, and where do clinicians want to see improvements?
- As potential single-administration cures, how will the treatment-eligible population change over time in indications served by a gene therapy?
- Who are the key decision-makers for gene therapy purchases and administration?
- What are the key drivers of and barriers to the adoption of gene therapies?
- What type of clinical trial data will be necessary to support the adoption and reimbursement of gene therapies?
- What is the clinical and commercial potential of emerging gene therapies in key therapy areas (e.g., ophthalmology, neurology)?
United States, EU5, Japan
Approximately 30 country-specific interviews with thought-leading gene therapy experts. Supported by survey data collected for this and other DRG research.
Diagnosed prevalent and/or incident patient populations eligible for gene therapies in covered indications.
Ten-year, annualized, drug-level sales and patient share of key gene therapies through 2029.
Pipeline gene therapy coverage for select indications across therapy areas, including hematology, ophthalmology, and neurology.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.